PuSH - Publikationsserver des Helmholtz Zentrums München: Repurposing Nitazoxanide to target the expanded r(CGG)<sub>n</sub> repeat RNA for therapeutic intervention in fragile-X tremor/Ataxia syndrome.

Informationen

Hinweise zu Qualitätskriterien von Zeitschriften

Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016

CC Licencences

Metriken für Publikationen

Navigation

Startseite

English

Recherche

Erweiterte Suche

Durchblättern nach ...

... HMGU-Autoren/Konsortien

... Organisationsstruktur

... Zeitschriften

... Publikationstypen

... Forschungsdaten

... Arbeitsgruppen

... Erscheinungsjahr

Publikationen im Überblick

Statistik

HGF Fortschrittsbericht

OA Publikationen

Eintragen

Neue Publikation eintragen

Neue Publikation holen aus...

...EVA

Fehlende Publikation melden

Highlights

Suche

Hilfe & Kontakt

Ansprechpartner

Hilfe

Datenschutz

Helmholtz Open Science

Bibliometrische Indikatoren

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Singh, K.* ; Shukla, S.* ; Kumari, A.P.* ; Qurashi, A.* ; Verma, A.K. ; Kumar, A.*

Repurposing Nitazoxanide to target the expanded r(CGG)_n repeat RNA for therapeutic intervention in fragile-X tremor/Ataxia syndrome.

Int. J. Biol. Macromol. 329:147864 (2025)

DOI

PMC

Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.

Abstract
Metriken
Zusatzinfos

Fragile X-associated Tremor/Ataxia Syndrome (FXTAS) is a debilitating neurodegenerative disorder linked to CGG trinucleotide repeat expansions in the FMR1 gene. These expanded repeats produce toxic FMR1poly-Glycine (FMR1polyG) proteins in neurons through mechanisms such as Repeat-Associated Non-AUG (RAN) translation and RNA foci formation, driving disease progression. In this study, we investigate the potential of Nitazoxanide (NTZ), a broad-spectrum antiparasitic and antiviral medication, as a therapeutic agent for FXTAS by targeting CGG repeat-associated toxicity. This comprehensive approach utilizing biophysical techniques, bioinformatic studies, cellular assays, and Drosophila models reveals NTZ's remarkable ability to bind specifically to toxic CGG repeat RNA, particularly GG mismatches, and to inhibit FMR1polyG aggregation. Biophysical methods, including Circular Dichroism (CD), Isothermal Titration Calorimetry (ITC), Electrophoretic Mobility Shift assays (EMSA), and Nuclear Magnetic Resonance (NMR) spectroscopy, accompanied with Molecular Docking, confirmed that NTZ effectively binds to CGG repeat RNA and mitigates its toxicity. Moreover, treatment with NTZ significantly reduced FMR1polyG-associated toxicity, corrected the splicing defects in FXTAS cell models, and improved different phenotypes in the Drosophila model of FXTAS. These compelling findings position NTZ as a promising candidate for neuroprotection in FXTAS, indicating its remarkable therapeutic potential and paving the way for future clinical applications to improve outcomes for the affected patients.

Impact Factor

Scopus SNIP

Altmetric

8.500

0.000

PuSH - Publikationsserver des Helmholtz Zentrums München

Repurposing Nitazoxanide to target the expanded r(CGG)n repeat RNA for therapeutic intervention in fragile-X tremor/Ataxia syndrome.

Repurposing Nitazoxanide to target the expanded r(CGG)_n repeat RNA for therapeutic intervention in fragile-X tremor/Ataxia syndrome.